Shun Devan Moodley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shun Devan Moodley has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- A M Setzer
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
1 shared publication A McDonald
ACTLIFE, Netcare Pretoria East Hospital, Pretoria, South Africa
1 shared publication- A Pincus
Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
1 shared publication - Adam Mahomed
University of the Witwatersrand
1 shared publication - Alicia McMaster
Sanofi-Aventis South Africa (Pty) Ltd
1 shared publication D Brittain
Wits Donald Gordon Medical Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by South African Medical Association NPC in South African Medical Journal
- p. e4675
Autologous haematopoietic stem cell transplantation in patients with multiple sclerosis: Experience from South Africa
Background. Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease that remains a major cause of neurological disability in young adults. While disease-modifying therapies (DMTs) can delay progression, many patients with highly active relapsing- remitting MS (RRMS) continue to experience breakthrough disease. Autologous haematopoietic stem cell transplantation (ASCT) offers durable immune reconstitution and remission but remains underutilised in upper-middle-income settings such as South Africa (SA). Objective. To evaluate the safety, feasibility and clinical outcomes of ASCT for MS in a real-world SA cohort. Methods. We conducted a retrospective record review of all MS patients who underwent ASCT between 1 January 2009 and 31 December 2024 at two JACIE-accredited tertiary centres (Wits Donald Gordon Medical Centre and Netcare Pretoria East Hospital). Data were extracted from institutional transplant records and analysed using descriptive statistics and Kaplan-Meier survival estimates. The primary outcome was the safety of ASCT for MS, and the secondary outcomes were the clinical outcomes of patients who underwent ASCT for MS. Results. Thirty-two patients were included (median age 42 years; 53% female; 94% RRMS). Median disease duration prior to ASCT was 7.4 years, and 97% had received prior DMTs. Conditioning included cyclophosphamide (97%), anti-thymocyte globulin (69%) and fludarabine (34%). The median neutrophil and platelet engraftment occurred at 10 and 14 days, respectively. Relapse-free survival was 100% at 1 year and 91% (95% confidence interval 68 - 98) at 5 years. Approximately 90% of evaluable patients demonstrated neurological improvement or stabilisation at 1 year. Treatment-related adverse events occurred in 63% of cases, and 95% of these side-effects were grade 3 or less: most commonly neutropenic fever (50%) and mucositis (16%). Only 5% of adverse reactions were grade 4, with no transplant-related mortality. Conclusion. ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA. Its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs. The expansion of accredited national ASCT programmes and registry-based outcome monitoring is warranted.
- 2 October 2026
- Published by South African Medical Association NPC in South African Medical Journal
- p. e4675
Open AccessAutologous haematopoietic stem cell transplantation in patients with multiple sclerosis: Experience from South Africa
Background. Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease that remains a major cause of neurological disability in young adults. While disease-modifying therapies (DMTs) can delay progression, many patients with highly active relapsing- remitting MS (RRMS) continue to experience breakthrough disease. Autologous haematopoietic stem cell transplantation (ASCT) offers durable immune reconstitution and remission but remains underutilised in upper-middle-income settings such as South Africa (SA). Objective. To evaluate the safety, feasibility and clinical outcomes of ASCT for MS in a real-world SA cohort. Methods. We conducted a retrospective record review of all MS patients who underwent ASCT between 1 January 2009 and 31 December 2024 at two JACIE-accredited tertiary centres (Wits Donald Gordon Medical Centre and Netcare Pretoria East Hospital). Data were extracted from institutional transplant records and analysed using descriptive statistics and Kaplan-Meier survival estimates. The primary outcome was the safety of ASCT for MS, and the secondary outcomes were the clinical outcomes of patients who underwent ASCT for MS. Results. Thirty-two patients were included (median age 42 years; 53% female; 94% RRMS). Median disease duration prior to ASCT was 7.4 years, and 97% had received prior DMTs. Conditioning included cyclophosphamide (97%), anti-thymocyte globulin (69%) and fludarabine (34%). The median neutrophil and platelet engraftment occurred at 10 and 14 days, respectively. Relapse-free survival was 100% at 1 year and 91% (95% confidence interval 68 - 98) at 5 years. Approximately 90% of evaluable patients demonstrated neurological improvement or stabilisation at 1 year. Treatment-related adverse events occurred in 63% of cases, and 95% of these side-effects were grade 3 or less: most commonly neutropenic fever (50%) and mucositis (16%). Only 5% of adverse reactions were grade 4, with no transplant-related mortality. Conclusion. ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA. Its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs. The expansion of accredited national ASCT programmes and registry-based outcome monitoring is warranted.
- Open Access
- 11 December 2013
- Published by Wiley in Journal of Cancer Research
- Vol. 2013, 1-5
Taxpas: Epidemiological and Survival Data in Breast Cancer Patients Treated with a Docetaxel-Based Chemotherapy Regimen in South Africa
Breast cancer is the leading cancer among South African women. There is limited South African epidemiological data on triple-negative breast cancer (TNBC). Taxpas was a nonrandomized observational survey conducted in multiple centres in South Africa from April 2004 to December 2010. 1632 female patients diagnosed with breast cancer, with a median age of 51 years, were enrolled in the survey. Patients were treated on a docetaxel-based chemotherapy regimen. The objective of the study was to assess epidemiological data and survival data. The incidence of TNBC was 14%. The one-year survival rate for the total cohort was 84%. The one-year survival rate for patients with early stage and metastatic breast cancer was recorded as 94% and 65%, respectively. Patients with TNBC stage III (all ages) and stage IV (≤50 years) had statistically significant worse 1-year survival rate compared to N-TNBC patients of the same age and stages. Conclusion. The incidence of TNBC in South Africa which is 14% is comparable to global incidence. The 1-year survival data for certain subgroups supports the literature saying that TNBC carries a worse prognosis compared to N-TNBC. Women ≤50 years diagnosed with late stage TNBC carried the worst prognosis in this survey.
- 11 December 2013
- Published by Wiley in Journal of Cancer Research
- Vol. 2013, 1-5
Open AccessTaxpas: Epidemiological and Survival Data in Breast Cancer Patients Treated with a Docetaxel-Based Chemotherapy Regimen in South Africa
Breast cancer is the leading cancer among South African women. There is limited South African epidemiological data on triple-negative breast cancer (TNBC). Taxpas was a nonrandomized observational survey conducted in multiple centres in South Africa from April 2004 to December 2010. 1632 female patients diagnosed with breast cancer, with a median age of 51 years, were enrolled in the survey. Patients were treated on a docetaxel-based chemotherapy regimen. The objective of the study was to assess epidemiological data and survival data. The incidence of TNBC was 14%. The one-year survival rate for the total cohort was 84%. The one-year survival rate for patients with early stage and metastatic breast cancer was recorded as 94% and 65%, respectively. Patients with TNBC stage III (all ages) and stage IV (≤50 years) had statistically significant worse 1-year survival rate compared to N-TNBC patients of the same age and stages. Conclusion. The incidence of TNBC in South Africa which is 14% is comparable to global incidence. The 1-year survival data for certain subgroups supports the literature saying that TNBC carries a worse prognosis compared to N-TNBC. Women ≤50 years diagnosed with late stage TNBC carried the worst prognosis in this survey.